SMID Biotech Access Fund LP
Raised
$250K
Investors
4
Min Invest
$50,000
Is this your company or fund? Claim this page free.
AltStreet Analysis
·Generated from EDGAR primary sources
SMID Biotech Access Fund LP is a Delaware limited partnership filed January 29, 2026, under Rule 506(c). The fund raised $250K from 4 investors with a $50K minimum investment. It is linked to the UpMarket platform, a pre-IPO investment sponsor with 30 related EDGAR entities.
This pre-IPO pooled investment fund uses the Rule 506(c) exemption, permitting general solicitation with verified accredited investors. The $50K minimum investment positions it in the accessible-retail tier for pre-IPO vehicles, consistent with platform-driven distribution models that aggregate smaller accredited checks into thematic exposure funds.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
1
latest Jan 29, 2026
Critical / warning
0 / 0
0 watch · 1 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
1
raising
Latest event New filer · Jan 29, 2026
SEC.govInvestor
- The dated record: 9 facts with source, effective date and capture date, viewable as AltStreet knew them on any past day
- 1 filing event with values and deltas, latest 2026-01-29, and alerts on the next one
- 1 offering timeline: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Hui Chen
Director · NEW YORK, NY
Placement Agents and Sales Compensation (Form D)
Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.
Upmarket Securities LLC
NEW YORK, NY · Soliciting in AK, AR, AZ, CA, CO, CT, DC, DE, FL, GA, ID, IL, LA, MA, MD, ME, MI, MN, MT, NC, NH, NJ, NM, NV, NY, OH, OK, OR, PA, PR, RI, SC, TN, TX, UT, VA, WA, WI
Questions About SMID Biotech Access Fund LP
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is SMID Biotech Access Fund LP?
SMID Biotech Access Fund LP is a Delaware limited partnership that filed a Form D with the SEC on January 29, 2026 in the Other industry group. The filing claims Rule 506(c) for an offering of pooled investment fund interests. AltStreet links the issuer to UpMarket.
Is SMID Biotech Access Fund LP legit?
AltStreet does not rate legitimacy; it reports the public record. SMID Biotech Access Fund LP filed a Form D with the SEC on January 29, 2026 claiming Rule 506(c). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $250,000 sold to 4 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. The issuer is linked to UpMarket, which AltStreet has reviewed. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is SMID Biotech Access Fund LP registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that SMID Biotech Access Fund LP claimed Rule 506(c) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has SMID Biotech Access Fund LP raised?
SMID Biotech Access Fund LP reported $250,000 sold from 4 investors in an offering of indefinite size as of the Form D filed January 29, 2026.
Who can invest in SMID Biotech Access Fund LP?
The offering relies on Rule 506(c), so the issuer may advertise it but may sell only to investors it has verified as accredited. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $50,000.
What is the minimum investment in SMID Biotech Access Fund LP?
The Form D lists $50,000 as the minimum investment accepted from any outside investor as of January 29, 2026. Issuers can waive their own minimums, and the figure does not include fees.
Who is selling SMID Biotech Access Fund LP and how are they paid?
The Form D names Upmarket Securities LLC as the recipient of sales compensation soliciting in AK, AR, AZ, CA, CO, CT, DC, DE, FL, GA, ID, IL, LA, MA, MD, ME, MI, MN, MT, NC, NH, NJ, NM, NV, NY, OH, OK, OR, PA, PR, RI, SC, TN, TX, UT, VA, WA, WI. Sales commissions are reported as $250 and finders' fees as $0. Form D allows these to be estimates.
Who is behind SMID Biotech Access Fund LP?
The Form D lists 1 related person: Hui Chen, director. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is SMID Biotech Access Fund LP located?
The issuer's address on its SEC filings is 1325 Avenue of the Americas, New York, NY 10019. Its phone number of record is 5162814242. It is organized under the laws of Delaware.
How long is the SMID Biotech Access Fund LP offering open?
The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.
What is SMID Biotech Access Fund LP's revenue?
The issuer declined to disclose its revenue range on the Form D, which the form permits.
Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Platform verification: the separate analyst-reviewed program for platforms, with right of reply and a document library.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.